Torsdag 5 December | 08:04:48 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-11-12 07:30 Kvartalsrapport 2025-Q3
2025-08-20 07:30 Kvartalsrapport 2025-Q2
2025-05-14 07:30 Kvartalsrapport 2025-Q1
2025-03-26 N/A Årsstämma
2025-02-05 07:30 Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-15 - Kvartalsrapport 2024-Q1
2024-03-21 - X-dag ordinarie utdelning HLUN B 0.70 DKK
2024-03-21 - X-dag ordinarie utdelning HLUN A 0.70 DKK
2024-03-20 - Årsstämma
2024-02-07 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-16 - Kvartalsrapport 2023-Q2
2023-05-10 - Kvartalsrapport 2023-Q1
2023-03-22 - X-dag ordinarie utdelning HLUN B 0.58 DKK
2023-03-22 - X-dag ordinarie utdelning HLUN A 0.58 DKK
2023-03-21 - Årsstämma
2023-02-08 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-06-10 - Split HLUN B 1:5
2022-06-08 - Extra Bolagsstämma 2022
2022-05-11 - Kvartalsrapport 2022-Q1
2022-03-24 - X-dag ordinarie utdelning HLUN B 2.00 DKK
2022-03-23 - Årsstämma
2022-02-09 - Bokslutskommuniké 2021
2021-11-10 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-11 - Kvartalsrapport 2021-Q1
2021-03-24 - X-dag ordinarie utdelning HLUN B 2.50 DKK
2021-03-23 - Årsstämma
2021-02-04 - Bokslutskommuniké 2020
2020-11-03 - Kvartalsrapport 2020-Q3
2020-08-13 - Kvartalsrapport 2020-Q2
2020-05-12 - Kvartalsrapport 2020-Q1
2020-03-25 - X-dag ordinarie utdelning HLUN B 4.10 DKK
2020-03-24 - Årsstämma
2020-02-06 - Bokslutskommuniké 2019
2019-11-05 - Kvartalsrapport 2019-Q3
2019-08-14 - Kvartalsrapport 2019-Q2
2019-05-08 - Kvartalsrapport 2019-Q1
2019-03-27 - X-dag ordinarie utdelning HLUN B 12.00 DKK
2019-03-26 - Årsstämma
2019-02-05 - Bokslutskommuniké 2018
2018-11-07 - Kvartalsrapport 2018-Q3
2018-08-08 - Kvartalsrapport 2018-Q2
2018-05-08 - Kvartalsrapport 2018-Q1
2018-03-21 - X-dag ordinarie utdelning HLUN B 8.00 DKK
2018-03-20 - Årsstämma
2018-02-07 - Bokslutskommuniké 2017
2017-11-08 - Kvartalsrapport 2017-Q3
2017-08-09 - Kvartalsrapport 2017-Q2
2017-05-10 - Kvartalsrapport 2017-Q1
2017-03-31 - X-dag ordinarie utdelning HLUN B 2.45 DKK
2017-03-30 - Årsstämma
2017-02-08 - Bokslutskommuniké 2016
2016-11-02 - Kvartalsrapport 2016-Q3
2016-08-24 - Kvartalsrapport 2016-Q2
2016-05-11 - Kvartalsrapport 2016-Q1
2016-04-01 - X-dag ordinarie utdelning HLUN B 0.00 DKK
2016-03-31 - Årsstämma
2016-02-10 - Bokslutskommuniké 2015
2015-11-04 - Kvartalsrapport 2015-Q3
2015-08-19 - Kvartalsrapport 2015-Q2
2015-05-06 - Kvartalsrapport 2015-Q1
2015-03-26 - X-dag ordinarie utdelning HLUN B 0.00 DKK
2015-03-25 - Årsstämma
2015-02-05 - Bokslutskommuniké 2014
2014-11-05 - Kvartalsrapport 2014-Q3
2014-08-07 - Kvartalsrapport 2014-Q2
2014-05-07 - Kvartalsrapport 2014-Q1
2014-03-27 - X-dag ordinarie utdelning HLUN B 2.77 DKK
2014-03-26 - Årsstämma
2014-02-06 - Bokslutskommuniké 2013
2013-11-06 - Kvartalsrapport 2013-Q3
2013-08-07 - Kvartalsrapport 2013-Q2
2013-05-01 - Kvartalsrapport 2013-Q1
2013-03-22 - X-dag ordinarie utdelning HLUN B 2.00 DKK
2013-03-21 - Årsstämma
2013-02-06 - Bokslutskommuniké 2012
2012-11-07 - Kvartalsrapport 2012-Q3
2012-08-08 - Kvartalsrapport 2012-Q2
2012-05-02 - Kvartalsrapport 2012-Q1
2012-03-30 - X-dag ordinarie utdelning HLUN B 3.49 DKK
2012-03-29 - Årsstämma
2012-02-08 - Bokslutskommuniké 2011
2011-11-09 - Kvartalsrapport 2011-Q3
2011-08-10 - Kvartalsrapport 2011-Q2
2011-05-04 - Kvartalsrapport 2011-Q1
2011-03-31 - X-dag ordinarie utdelning HLUN B 3.77 DKK
2011-03-30 - Årsstämma
2010-04-21 - X-dag ordinarie utdelning HLUN B 3.07 DKK
2009-04-22 - X-dag ordinarie utdelning HLUN B 2.30 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriLäkemedel & Handel
Lundbeck är ett läkemedelsbolag. Störst fokus återfinns inom forskning om psykiatriska och neurotiska störningar, vilket innefattar behandling av depression, schizofreni, Alzheimers och Parkinsons syndrom. Bolaget bedriver forskning, utveckling och distribution av läkemedel där kundbasen återfinns på global nivå. Bolaget grundades ursprungligen under 1915 och har sitt huvudkontor i Valby.
2024-06-19 08:30:00

Lundbeck is exploring a new area in neurohormonal dysfunctions by initiating a phase II trial using Lu AG13909 as a potential treatment for Cushing's disease. This marks an important step in Lundbeck's commitment to advancing promising scientific innovations.

H. Lundbeck A/S (Lundbeck) is enhancing its research and development in neurohormonal dysfunctions.

A key part of this strategy is the development of Lu AG13909, a first-in-class monoclonal antibody (mAb) that targets the adrenocorticotropic hormone (ACTH).

By binding to ACTH with high affinity, Lu AG13909 aims to reduce elevated ACTH levels, potentially providing therapeutic benefits for individuals with neurohormonal dysfunctions.[1]

In a recent development, a phase II clinical trial assessing efficacy, safety, and tolerability of Lu AG13909 as a potential treatment for Cushing's disease, has been initiated.

"We are pleased to advance this new approach to potentially treating unmet needs in Cushing's disease, a condition that, when uncontrolled, is debilitating and increases mortality," said Johan Luthman, EVP and Head of Research & Development at Lundbeck.

With the latest initiated trial, Lundbeck is currently investigating Lu AG13909 for two conditions: Cushing's disease and congenital adrenal hyperplasia.[2]

These ongoing clinical trials underscore Lundbeck's commitment to innovation and expanding treatment options for people with rare neurohormonal dysfunctions.

Lu AG13909: A potential treatment for people with Cushing's disease
Cushing's disease is a serious condition caused by a pituitary adenoma leading to excessive production of ACTH, which in turn stimulates the adrenal glands to produce high levels of cortisol. This hormonal imbalance results in clinical manifestations such as weight gain, fatigue, muscle weakness, hypertension, diabetes, obesity, and can lead to early death.[3 4]

Lu AG13909, a potential cornerstone in the pharmacological treatment of Cushing's disease, is an antibody designed to target ACTH with high precision thereby neutralising the actions of ACTH.[1] Consequently, Lu AG13909 is expected to reduce pathologically elevated ACTH signaling and thus provide a therapeutic benefit to patients with Cushing's disease. This innovative approach may be a significant step forward in managing the disease.

Lu AG13909: Unveiling new possibilities for people with congenital adrenal hyperplasia
Congenital adrenal hyperplasia is a rare disorder characterized by an enzyme deficiency which disrupts adrenal steroidogenesis leading to cortisol and aldosterone deficiency and consequently increased ACTH levels. The increased ACTH levels stimulate the adrenal glands, leading to adrenal hyperplasia and androgen excess, causing the clinical features of congenital adrenal hyperplasia.[5-7]

People with congenital adrenal hyperplasia are at risk of adrenal crisis, a life-threatening condition. The challenge lies in balancing glucocorticoid replacement therapy and controlling hyperandrogenism, with the risk of long-term consequences of glucocorticoid overtreatment.[8-11]

Contacts

Thomas Mikkel Mortensen Palle Holm Olesen
Media Relations Lead, Corp. Communication Vice President, Investor Relations
THMR@lundbeck.com PALO@lundbeck.com (PALO@lundbeck.com)
+45 30 83 30 24 +45 30 83 24 26

About H. Lundbeck A/S
Lundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options.

Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of. 

For additional information, we encourage you to visit our corporate site www.lundbeck.com (https://www.lundbeck.com/global) and connect with us via LinkedIn (https://www.linkedin.com/company/lundbeck/).

References
1. Feldhaus AL, Anderson K, Dutzar B, et al. ALD1613, a Novel Long-Acting Monoclonal Antibody to Control ACTH-Driven Pharmacology. Endocrinology 2017;158(1):1-8. doi: 10.1210/en.2016-1455

2. Clinicaltrials.gov. ID NCT05669950  [Available from: https://clinicaltrials.gov/study/NCT05669950?cond=congenital%20adrenal%20hyperplasia&term=lundbeck&checkSpell=&rank=1.

3. Gallo-Payet N, Martinez A, Lacroix A. Editorial: ACTH Action in the Adrenal Cortex: From Molecular Biology to Pathophysiology. Front Endocrinol (Lausanne) 2017;8:101. doi: 10.3389/fendo.2017.00101 [published Online First: 20170612]

4. Lonser RR, Nieman L, Oldfield EH. Cushing's disease: pathobiology, diagnosis, and management. J Neurosurg 2017;126(2):404-17. doi: 10.3171/2016.1.Jns152119 [published Online First: 20160422]

5. Claahsen-van der Grinten HL, Speiser PW, Ahmed SF, et al. Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management. Endocr Rev 2022;43(1):91-159. doi: 10.1210/endrev/bnab016 [published Online First: 2021/05/08]

6. Merke DP, Auchus RJ. Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. N Engl J Med 2020;383(13):1248-61. doi: 10.1056/NEJMra1909786 [published Online First: 2020/09/24]

7. El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet 2017;390(10108):2194-210. doi: 10.1016/s0140-6736(17)31431-9 [published Online First: 2017/06/04]

8. Auchus RJ, Courtillot C, Dobs A, et al. Treatment patterns and unmet needs in adults with classic congenital adrenal hyperplasia: A modified Delphi consensus study. Front Endocrinol (Lausanne) 2022;13:1005963. doi: 10.3389/fendo.2022.1005963 [published Online First: 20221118]

9. Han TS, Walker BR, Arlt W, Ross RJ. Treatment and health outcomes in adults with congenital adrenal hyperplasia. Nat Rev Endocrinol 2014;10(2):115-24. doi: 10.1038/nrendo.2013.239 [published Online First: 20131217]

10. Lousada LM, Mendonca BB, Bachega T. Adrenal crisis and mortality rate in adrenal insufficiency and congenital adrenal hyperplasia. Arch Endocrinol Metab 2021;65(4):488-94. doi: 10.20945/2359-3997000000392 [published Online First: 20210716]

11. Pofi R, Ji X, Krone NP, Tomlinson JW. Long-term health consequences of congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2023 doi: 10.1111/cen.14967 [published Online First: 20230907]